tradingkey.logo

Apyx Medical Corp

APYX
3.350USD
+0.210+6.69%
Close 11/06, 16:00ETQuotes delayed by 15 min
126.61MMarket Cap
LossP/E TTM

Apyx Medical Corp

3.350
+0.210+6.69%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Apyx Medical Corp

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Apyx Medical Corp's Score

Industry at a Glance

Industry Ranking
109 / 210
Overall Ranking
245 / 4616
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
4.000
Target Price
+23.46%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Apyx Medical Corp Highlights

StrengthsRisks
Apyx Medical Corporation is an advanced energy technology company. The Company's segments include Advanced Energy and OEM. The Advanced Energy segment's product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It is focused on the cosmetic surgery market where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians an ability to provide controlled heat to the tissue to achieve their desired results. Its product lines consist of a multifunction generator, a handpiece and a supply of helium gas. The OEM segment leverages its expertise in the design, development and manufacturing of electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers through original equipment manufacturing agreements, as well as start-up companies with the need for its energy-based designs.
Growing
The company is in a growing phase, with the latest annual income totaling USD 48.10M.
Undervalued
The company’s latest PE is -7.03, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 16.33M shares, decreasing 20.51% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 2.44M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 7.78, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 11.37M, representing a year-over-year decrease of 6.39%, while its net profit experienced a year-over-year decrease of 42.37%.

Score

Industry at a Glance

Previous score
7.78
Change
0

Financials

6.83

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

6.98

Operational Efficiency

9.85

Growth Potential

7.92

Shareholder Returns

7.33

Apyx Medical Corp's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 6.97, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -7.03, which is -82.45% below the recent high of -1.23 and -87.20% above the recent low of -13.15.

Score

Industry at a Glance

Previous score
6.97
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 109/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 7.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Apyx Medical Corp is 4.00, with a high of 4.00 and a low of 4.00.

Score

Industry at a Glance

Previous score
7.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts
Buy
Current Rating
4.500
Target Price
+43.31%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

110
Total
7
Median
9
Average
Company name
Ratings
Analysts
Apyx Medical Corp
APYX
4
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Dexcom Inc
DXCM
30
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 7.37, which is higher than the Healthcare Equipment & Supplies industry's average of 6.82. Sideways: Currently, the stock price is trading between the resistance level at 3.55 and the support level at 2.68, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
8.72
Change
-1.35

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(3)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.019
Neutral
RSI(14)
63.622
Neutral
STOCH(KDJ)(9,3,3)
66.246
Neutral
ATR(14)
0.236
High Vlolatility
CCI(14)
247.315
Overbought
Williams %R
36.578
Buy
TRIX(12,20)
0.906
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
3.192
Buy
MA10
3.130
Buy
MA20
3.098
Buy
MA50
2.555
Buy
MA100
2.339
Buy
MA200
1.828
Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.40. The latest institutional shareholding proportion is 43.18%, representing a quarter-over-quarter decrease of 26.03%. The largest institutional shareholder is Chuck Royce, holding a total of 2.44M shares, representing 6.45% of shares outstanding, with 6.78% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Nantahala Capital Management, LLC
3.34M
+2.46%
Archon Capital Management LLC
3.28M
-0.46%
Vanderfelt (William Weeks)
3.16M
--
Royce Investment Partners
Star Investors
2.44M
-3.40%
Vizirgianakis (Stavros G)
1.75M
--
The Vanguard Group, Inc.
Star Investors
1.48M
--
Silverberg Bernstein Capital Management, LLC
986.50K
+10.01%
Commonwealth Financial Network
663.54K
+13.32%
Horizon Kinetics LLC
Star Investors
615.00K
--
BlackRock Institutional Trust Company, N.A.
495.99K
+1.40%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 2.01, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 1.51. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
2.01
Change
0
Beta vs S&P 500 index
1.51
VaR
+7.76%
240-Day Maximum Drawdown
+54.13%
240-Day Volatility
+131.28%

Return

Best Daily Return
60 days
+20.92%
120 days
+20.92%
5 years
+51.89%
Worst Daily Return
60 days
-11.79%
120 days
-19.01%
5 years
-60.45%
Sharpe Ratio
60 days
+2.30
120 days
+2.19
5 years
+0.30

Risk Assessment

Maximum Drawdown
240 days
+54.13%
3 years
+88.52%
5 years
+94.99%
Return-to-Drawdown Ratio
240 days
+2.57
3 years
+0.25
5 years
-0.14
Skewness
240 days
+1.26
3 years
+1.00
5 years
+0.26

Volatility

Realised Volatility
240 days
+131.28%
5 years
+108.05%
Standardised True Range
240 days
+5.50%
5 years
+10.52%
Downside Risk-Adjusted Return
120 days
+371.54%
240 days
+371.54%
Maximum Daily Upside Volatility
60 days
+79.29%
Maximum Daily Downside Volatility
60 days
+65.07%

Liquidity

Average Turnover Rate
60 days
+0.24%
120 days
+0.37%
5 years
--
Turnover Deviation
20 days
-26.71%
60 days
-14.55%
120 days
+29.10%

Peer Comparison

Healthcare Equipment & Supplies
Apyx Medical Corp
Apyx Medical Corp
APYX
6.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI